Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 14, 2022

View Archived Issues

NOS targeting to treat ischemic stroke

Serum PRO-C6 monitors and predicts infliximab response in patients with Crohn's disease

New TLR8 agonists identified at National Institute of Pharmaceutical R&D Co.

FLT3 inhibitors discovered at Cytosinlab Therapeutics

Janssen Pharmaceutica presents new factor XIa inhibitors

Roche patents vasopressin V1A receptor antagonists

Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical identify new SOS1 inhibitors

Targeting sphingolipid synthesis has multiple beneficial effects in Duchenne model

SAF-248 shows potent activity against DLBCL in vitro and in vivo

STC-2 administration confers post-stroke functional recovery in a preclinical model

R2M3-26, a novel Wnt mimetic with promising efficacy in mouse model of colitis

3-beta-HSD linked to depression in males due to testosterone degradation

JN Nova advances COVID-19 therapeutic JN-2019 into clinic

T-cell evasion is one pressure shaping SARS-CoV-2 evolution

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 5, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...
How to Summit up? Dis-Harmoni on ivonescimab NSCLC phase III
BioWorld
Wall Street pundits were divided about the likely fate of ivonescimab, Summit Therapeutics Inc.’s bispecific antibody partnered with Akeso Pharmaceuticals Inc.,...